186 related articles for article (PubMed ID: 38481843)
1. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review.
Machado S; Cruz A; Ferreira PL; Morais C; Pimenta RE
Front Public Health; 2024; 12():1263472. PubMed ID: 38481843
[TBL] [Abstract][Full Text] [Related]
2. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S; Schneider P; Zuba M; Busse R; Panteli D
Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
[No Abstract] [Full Text] [Related]
3. Policies for biosimilar uptake in Europe: An overview.
Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
[TBL] [Abstract][Full Text] [Related]
4. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.
Leonard E; Wascovich M; Oskouei S; Gurz P; Carpenter D
J Manag Care Spec Pharm; 2019 Jan; 25(1):102-112. PubMed ID: 30589628
[TBL] [Abstract][Full Text] [Related]
5. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
6. Postmarket policy considerations for biosimilar oncology drugs.
Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of biosimilar uptake in emerging markets.
Chhabra H; Mouslim MC; Kashiramka S; Rathore AS
Expert Opin Biol Ther; 2022 Jun; 22(6):679-688. PubMed ID: 35535988
[TBL] [Abstract][Full Text] [Related]
9. Incentives for market penetration of biosimilars in Belgium and in five European countries.
Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
[TBL] [Abstract][Full Text] [Related]
10. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
11. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
[TBL] [Abstract][Full Text] [Related]
12. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
Rémuzat C; Kapuśniak A; Caban A; Ionescu D; Radière G; Mendoza C; Toumi M
J Mark Access Health Policy; 2017; 5(1):1307315. PubMed ID: 28740617
[TBL] [Abstract][Full Text] [Related]
13. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
14. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
15. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
[TBL] [Abstract][Full Text] [Related]
16. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
17. Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies.
Mohd Sani N; Aziz Z; Kamarulzaman A
BioDrugs; 2024 May; 38(3):405-423. PubMed ID: 38472644
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
[No Abstract] [Full Text] [Related]
19. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
[TBL] [Abstract][Full Text] [Related]
20. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
